Protein Binding Assays Market Gains from Rising CRO Collaborations

In 2023, the global protein binding assays market was valued at USD 455.6 million. It is anticipated to expand to USD 896.3 million by 2030, reflecting a Compound Annual Growth Rate (CAGR) of 10.2% over the forecast span from 2024 to 2030. Protein binding assays are biochemical and molecular‐biology tools used to examine interactions among proteins, nucleic acids, or combinations thereof.

Key Market Trends & Insights

• In 2023, North America held the largest regional share of the market, at 40.8%.
• The Asia Pacific region is projected to grow the fastest, with a CAGR of 11.1% over the forecast period.
• By product & services category, the services segment was dominant in 2023, capturing 44.7% of the market.
• With respect to end‐use, pharmaceuticals and biotechnology led with a 46.4% share in 2023.
• Among technologies, equilibrium dialysis was the most used in 2023, with a share of 49.7%.

Market Size & Forecast

• 2023 market size: USD 455.6 million.
• Projected 2030 market size: USD 896.3 million.
• CAGR (2024-2030): 10.2%.
• Largest region in 2023: North America.
• Fastest-growing region over forecast: Asia Pacific.

Drivers include increased prevalence of chronic diseases necessitating more thorough drug assessments; rising R&D expenditure; the launch of more effective new drugs; demand for assay methods that are faster and more efficient. There is growing emphasis on technologies offering high accuracy and sensitivity, as well as on collaborations among pharmaceutical companies, biotech firms, and contract research organizations (CROs).

Key Companies & Market Share Insight

Major players in this market are focusing on strengthening their competitive positions through strategic moves—such as mergers, acquisitions, partnerships—and technology innovation. They are developing more refined assays and integrating advanced features like improved sensitivity and analytical precision to meet increasing demand from preclinical and clinical drug discovery, diagnostics, and therapeutics.

Order a free sample PDF of the Protein Binding Assays Market Intelligence Study, published by Grand View Research.

Some are scaling up their services to cater not only to established pharmaceutical customers but also small biotech firms and CROs. Other companies are enhancing kits, reagents, and instrumentation in order to offer more turnkey solutions.

Key Companies

• Thermo Fisher Scientific
• ADMEcell, Inc.
• Beckman Coulter, Inc.
• Sartorius AG
• Bio-Rad Laboratories, Inc.
• Abzena Ltd
• Abcam Limited
• GVK Biosciences Private Limited
• Promega Corporation
• Arrayit Corporation
• Charles River Laboratories
• Sovicell
• Eurofins Scientific
• 3B Pharmaceuticals
• Creative Biolabs
• Evotec SE
• BioDuro-Sundia
• Merck KGaA

Conclusion

The protein binding assays market is set to nearly double in size from 2023 to 2030, driven by robust growth in Asia Pacific, major technological advances, and increased demand from pharmaceuticals and CROs alike. Equilibrium dialysis remains dominant for now, but segments such as services, high‐throughput techniques, and superior sensitivity in kits and reagents are gaining traction. Competitive dynamics favor companies that can innovate, collaborate, and supply comprehensive solutions globally; future success will likely hinge on adaptability, quality, and strategic positioning in both established and emerging markets.

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.